Cas:51336-47-1 ethyl 2-(4-bromo-2-formylphenoxy)acetate manufacturer & supplier

We serve Chemical Name:ethyl 2-(4-bromo-2-formylphenoxy)acetate CAS:51336-47-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

ethyl 2-(4-bromo-2-formylphenoxy)acetate

Chemical Name:ethyl 2-(4-bromo-2-formylphenoxy)acetate
CAS.NO:51336-47-1
Synonyms:ethyl (4-bromo-2-formylphenoxy)acetate;(4-bromo-2-formylphenoxy)-acetic acid ethyl ester;2-formyl-4-bromophenoxyacetic acid ethyl ester;ethyl-2-formyl-4-bromophenoxy acetate
Molecular Formula:C11H11BrO4
Molecular Weight:287.10700
HS Code:2918990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:52.60000
Exact Mass:285.98400
LogP:2.20350

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like ethyl (4-bromo-2-formylphenoxy)acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,ethyl-2-formyl-4-bromophenoxy acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-formyl-4-bromophenoxyacetic acid ethyl ester Use and application,2-formyl-4-bromophenoxyacetic acid ethyl ester technical grade,usp/ep/jp grade.


Related News: The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. ethyl 2-(4-bromo-2-formylphenoxy)acetate manufacturer Some of Amanpour’s counterparts also offered well-wishes on Monday. ethyl 2-(4-bromo-2-formylphenoxy)acetate supplier The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. ethyl 2-(4-bromo-2-formylphenoxy)acetate vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). ethyl 2-(4-bromo-2-formylphenoxy)acetate factory The victim — who died Saturday — was a 44-year-Chinese man who flew in from Wuhan in January.